ProteLight Pharmaceuticals (Jiangsu) Co., Ltd.

普莱医药（江苏）股份有限公司

Develops antimicrobial peptide therapeutics focusing on anti-infectives and metabolic diseases. Core product PL-5 (Peceleganan) is a topical spray treating secondary infections of burn wounds and diabetic foot infections. Operates in China.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Social insurance & housing fund
• Data, cybersecurity & privacy
• Other
• Customer concentration
• Supplier concentration
• Distribution model
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Capacity and utilisation
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Investments and fair-value assets
• Adverse change after the track record
• Chapter 18A biotech
• Sanctioned countries and export controls